

Effects of structuring doctor-patient-communication in primary care of patients with multimorbidity (MultiCare AGENDA)

Submission date 01/09/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 28/11/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/02/2018	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Hanna Kaduszkiewicz

Contact details
University Medical Center Hamburg-Eppendorf
Department of Primary Medical Care
Martinistr. 52
Hamburg
Germany
20246
-
kaduszk@uke.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Effects of structuring doctor-patient-communication in primary care of patients with multimorbidity (MultiCare AGENDA): a multi-center, parallel group, cluster-randomized controlled trial

Acronym

MultiCare AGENDA

Study objectives

We assume that the number of pharmaceutical agents taken by the patient can be reduced in the intervention group. We will compare the change in medication intake between baseline and follow-up in the intervention and control group. We expect that the mean difference between the changes in both groups will be at least 1.5 drugs less in the intervention group. A minimum difference of 0.5 drugs between both groups is defined as clinically relevant.

In order to include a measure that reflects the subjectivity of the patient we will also measure the health related quality of life. It is assumed that a reduction of medications used will not impair quality of life. We will compare the change in health related quality of life as measured by EuroQoL EQ-5D, UK value set between baseline and follow-up in the intervention and control group. We expect that the mean change in the intervention group will not be statistically significantly inferior to the mean change in the control group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Medical Association of Hamburg approved on 1st July 2011, approval no. PV3788

Study design

Multi-center parallel group cluster-randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Multimorbidity

Interventions

The intervention consists of three special consultations by GPs for patients with multimorbidity.

The consultations comprise of:

1. Performing a narrative doctor-patient-dialogue aimed at carving out treatment targets and priorities of the patient
2. Performing a narrative patient-centred medication review, and
3. Performing a narrative doctor-patient-dialogue reflecting the attainment of treatment targets and priorities of the patient. Before the GPs in the intervention arm start with the respective consultations they will be trained by members of the study team.

Control arm: Care as usual

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

1. Number of pharmaceutical agents taken by the patient
 2. Health related quality of life as measured by the EuroQoL EQ-5D, UK value set
- Measured at baseline and post intervention (12 months)

Secondary outcome measures

1. GPs knowledge of the medication taken by patient
 2. Patient satisfaction with GP services as measured by the EUROPEP questionnaire
 3. Patient empowerment as measured by the Health Care Empowerment Questionnaire
 4. Health care utilization (e.g. contacts with GP and specialists, hospital admissions)
- Measured at baseline and post intervention (12 months)

Overall study start date

01/09/2011

Completion date

31/08/2013

Eligibility

Key inclusion criteria

1. Age 65-85 years at time of recruitment
2. At least one contact with the GP within the most recent quarter (3 months period)

Participant type(s)

Patient

Age group

Senior

Sex

Both

Target number of participants

Planned sample size: 600

Key exclusion criteria

1. Poorly known patients to the general practitioner (GP) because of accidental consultation
2. Patients that are treated by the GP for less than 12 months
3. Patients with less than 3 diagnoses out of a list of 42 groups of chronic diseases and syndromes
4. Insufficient ability to consent (e.g. dementia)
5. Insufficient ability to participate in studies (e.g. severe psychic illness)
6. Severe illness probably fatal within 3 months according to the GP
7. Residence in a nursing home
8. Deafness
9. Insufficient ability to speak and read German
10. Participation in other scientific trials

Date of first enrolment

01/09/2011

Date of final enrolment

31/08/2013

Locations

Countries of recruitment

Germany

Study participating centre

University Medical Center Hamburg-Eppendorf

Hamburg

Germany

20246

Sponsor information

Organisation

German Federal Ministry of Education and Research (Germany)

Sponsor details

Hannoversche Straße 28-30
Berlin
Germany
10115

-
information@bmbf.bund.de

Sponsor type

Government

ROR

<https://ror.org/04pz7b180>

Funder(s)

Funder type

Government

Funder Name

German Federal Ministry of Education and Research (Germany) (Funding no. 01ET1006A-K)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	12/12/2012		Yes	No
Results article	results	23/01/2018		Yes	No